Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Executive Summary
Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.
You may also be interested in...
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Celltrion's Herceptin Biosimilar One Step Closer To US FDA Approval
Following Oncologic Drugs Advisory Committee's recommendation for Mylan and Biocon's trastuzumab biosimilar, Celltrion and Teva's CT-P6 appear to be one of the next one in, but given the expiry of Herceptin patent in the US and other late stage trastuzumab biosimilar candidates, it could be anybody's game to launch their products first.